Merck: Q3 earnings and revenue beat estimates, cautious 2027 outlook
FROM THE WIRE · FINANCE.YAHOO.COM
Merck MRK announced strong third-quarter 2026 results on Oct. 29, with both adjusted earnings and revenues surpassing estimates. Third-quarter 2026 sales were $18.1 billion, up 5% year over year, while adjusted earnings declined 3% to $2.49 per share. Keytruda/Keytruda Qlex…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralMerck raised 2026 guidance but expects modest 2027 growth due to generic pressure.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 sales rose 5% to $18.1 billion.
- 02Keytruda sales rose 6% to $8.6 billion.
- 03Merck expects over $2 billion of generic headwinds in 2027.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets